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Available online 24 September 2015Receptor activator of nuclear factor-ĸB ligand (RANKL) and its decoy
receptor osteoprotegerin (OPG) are established as essential determi-
nants of bone health and a dysregulation of this system towards
RANKL results in osteoporosis (Rachner et al., 2011). Based on these
ﬁndings, denosumab, a monoclonal antibody directed against RANKL
was developed and has now been approved for the treatment of osteo-
porosis and bone metastases (Rachner et al., 2011).
In the past years, an additional role of the RANKL/OPG system in
mammary carcinogenesis has been recognized. Until now, most studies
addressing this topic have focused on the role of RANKL as the direct
effector molecule in this system. Two simultaneously published
studies in 2010 convincingly provided evidence to show that RANKL
mediates progestin-driven mammary carcinogenesis (Schramek et al.,
2010; Gonzalez-Suarez et al., 2010). Upon exposure of mice to proges-
terone or progesterone derivatives the local expression of RANKL is
highly increased in mammary cells. Increased carcinogenesis observed
in the presence of medroxyprogesterone and the carcinogen 7,12-
dimethylbenz(a)anthracene (DMBA) is prevented by both the genetic
inhibition of RANK, which acts as the receptor for RANKL (Schramek
et al., 2010) or by pharmacological inhibition of RANKL (Gonzalez-
Suarez et al., 2010). In addition, tumour-inﬁltrating regulatory T cells
have been shown to promote metastases by producing high levels of
RANKL (Tan et al., 2011).
In this issue of EBioMedicine, Widschwendter and colleagues extend
the scope of the RANKL/OPG system to women with BRCA-mutations
(Widschwendter et al., 2015). BRCA-mutations occur infrequently and
account for about 5 to 10% of all breast cancers and 15% of ovarianDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.08.037.
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2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article undercancers (Campeau et al., 2008). The lifetime risk of developing breast
cancer is drastically increased in women with a harmful mutation in
BRCA1 or BRCA2 compared to non-mutation carriers, however a clear
prediction with regard to cancer occurrence remains impossible.
In their analyses of almost 400 BRCA 1/2-mutation carriers,
Widschwendter et al. found OPG serum levels to be lower, most
notably in BRCA1-mutation carriers, compared to ~780 controls
(Widschwendter et al., 2015). In addition, free RANKL serum con-
centrations were also decreased in BRCA-mutation carriers. To
address this issue which may appear discrepant at ﬁrst, further studies
were conducted by comparing serum and tissue expression of RANKL
and OPG in ovariectomised adult female cynomolgusmacaques treated
with no hormones, oestrogens or an oestrogen/progestin combination.
While progestin treatment increased RANKL expression in themamma-
ry gland there were no differences in serum RANKL. On the other hand
lower levels of serum OPG following progestin treatment correlated
with a decreased expression in breast tissue. These results indicate
that – in contrast to RANKL – breast tissue derived OPG substantially
contributes to serum levels.
Finally, associations were made for serum RANKL and OPG and the
menopausal status as lack of ovarian function (i.e., postmenopausal
status) is known to protect from breast cancer. Serum levels of OPG
were higher in postmenopause as compared to premenopause,whereas
an opposite tendency was observed for RANKL. Even more compelling
evidence for a possible role of OPG in the risk prediction of breast cancer
was provided by the analysis of about 220 patients with distinct BRCA
mutations that are associated with different HR for breast cancer.
Therein, OPG serum levels were inversely associated with breast cancer
risk. In addition, low levels of OPG were associated with an increased
proliferation in the mammary gland as assessed by Ki67 measurement.
These results underline a role of the RANKL/OPG system in the
pathophysiology of breast cancer. Since the activity of RANKL is directly
determined by the presence of OPG, it is important to assess the concen-
tration of both proteins and theRANKL/OPG ratio has often been consid-
ered as a better indicator of RANKL activity than RANKL alone. However,
serum levels do not always reﬂect the situation at the tissue level. This
may be especially true for RANKL, where previous studies reported
elevated levels of RANKL in the cells of the bone microenvironment
in postmenopausal women, and while this increase was reversed
in women receiving hormone replacement therapy in bone cells,
no changes in serum RANKL were observed between the groups
(Eghbali-Fatourechi et al., 2003).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a BRCA mutation have received increased attention as a result of the
“Angelina Jolie Effect” (Evans et al., 2014). Despite the increasing aware-
ness, the uncertainty of the diagnosis with respect to breast cancer risk
and the potential need for risk-reducing mastectomy remain a signiﬁ-
cant psychological burden for numerous young women. Thus, deﬁning
novel methods to better predict the risk of developing breast cancer
and most importantly discover non-invasive preventive measures are
urgently needed.
In summary, results from this study provide a clear rationale for
further investigation of the RANKL/OPG system in breast cancer and
speciﬁcally in patients with BRCA 1/2-mutations.
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